Marc Allen

Seagen

Targeting Cancer. Transforming Therapies. Seagen is where revolutionary science meets transformative cancer therapy. Seagen is committed to advancing late-stage clinical trials and expanding the development of its portfolio both in and outside the U.S. to better the health of people with cancer. We are dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. We are focused on discovering, developing, manufacturing and commercializing targeted cancer therapeutics, with antibody-drug conjugates (ADCs) at our core. We work together with urgency to improve and extend the lives of people living with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability, and potency. We are working on expanding the four approved therapies for cancer while advancing new technologies with the potential to generate multiple Investigational New Drug Applications (INDs) that include next-generation ADC technologies and other novel cancer-targeting approaches.